All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-002509-63 | A double blind, randomised, placebo controlled, parallel group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis | 2005-12-20 | due-trials |
| Reported results | 2004-002530-20 | A double blind, randomised, placebo controlled, parallel group study of Sativex in the treatment of subjects with pain due to diabetic neuropathy | 2006-06-08 | due-trials |
| Reported results | 2004-002531-32 | A double blind, randomised, placebo controlled, parallel group study of Sativex, in the treatment of subjects with peripheral neuropathic pain associated with allodynia | 2006-10-18 | due-trials |
| Reported results | 2004-004395-36 | A Multi-Centre, Open Label, Follow-on Study to Assess the Maintenance of Effect, Tolerance and Safety of Sativex in the Treatment of Subjects with Neuropathic Pain | 2007-08-28 | due-trials |
| Reported results | 2005-005265-11 | A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple scler... | 2008-04-30 | due-trials |
| Reported results | 2006-001598-10 | A double blind, randomised, placebo controlled, parallel group study of Sativex® in the treatment of subjects with pain due to diabetic neuropathy | 2008-10-07 | due-trials |
| Reported results Terminated | 2006-003655-20 | A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of post-herpetic neuralgia. | 2008-10-07 | due-trials |
| Reported results | 2006-005910-11 | A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessm... | 2009-01-30 | due-trials |
| Reported results | 2007-002138-13 | A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®). | 2009-01-16 | due-trials |
| Completed, reported early | 2007-005225-30 | A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP DOSE-RANGE EXPLORATION STUDY OF SATIVEX IN RELIEVING PAIN IN PATIENTS WITH ADVANCED CANCER, WHO EXPERIENCE INADEQUATE ANALGESIA DURING OP... | 2041-01-04 | not-yet-due |
| Reported results | 2009-016064-36 | A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patie... | 2015-07-02 | due-trials |
| Reported results | 2009-016065-29 | A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patie... | 2014-11-24 | due-trials |
| Reported results | 2009-016529-32 | A multicenter, non-comparative, open-label extension study to assess the long term safety of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in patients with uncontrolled persist... | 2017-01-27 | due-trials |
| Reported results | 2009-017080-41 | A randomised, partially-blind, placebo-controlled, pilot, dose-ranging study to assess the effect of cannabidiol (CBD) on liver fat levels in subjects with fatty liver disease. | 2012-07-13 | due-trials |
| Reported results | 2010-020458-33 | A randomised, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GW42003: GW42004 plus GW42003 and GW42004 alone in the treatment of dyslipidaemia in sub... | 2012-02-07 | due-trials |
| Reported results | 2010-022905-17 | A two-part, placebo-controlled, study of the safety and efficacy of Sativex oromucosal spray (Sativex; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patients ... | 2015-12-28 | due-trials |
| Reported results Terminated | 2011-000180-28 | A randomised, double-blind, placebo-controlled parallel group, pilot study of 40:1 ratio of formulated GWP42003 : GWP42004 in the treatment of iatrogenic weight gain and dyslipidaemia associated with ... | 2012-10-01 | due-trials |
| Reported results | 2011-000926-31 | A Multicentre, Double-blind, Randomised Parallel Group, Placebo- controlled Study of the Effect of long-term treatment with Sativex on Cognitive Function and Mood of Patients with Spasticity due to Mu... | 2013-05-13 | due-trials |
| Reported results | 2011-003208-19 | A randomised, double-blind, placebo-controlled parallel group, pilot study of GWP42003 in the symptomatic treatment of ulcerative colitis. | 2014-08-04 | due-trials |
| Reported results | 2012-003771-18 | The efficacy, safety and tolerability of Sativex as an adjunctive treatment to existing anti-spasticity medications in children aged 8 to 18 years with spasticity due to cerebral palsy or traumatic ce... | 2017-03-23 | due-trials |
| Reported results | 2013-000212-22 | A double-blind, randomised, placebo-controlled, parallel group study of GWP42003 as adjunctive therapy in the first line treatment of schizophrenia or related psychotic disorder | 2015-01-08 | due-trials |
| Reported results | 2013-001140-61 | A randomised, double blind, placebo controlled, parallel group, dose ranging study of GWP42004 as add on to metformin in the treatment of participants with Type 2 diabetes. | 2015-12-29 | due-trials |
| Reported results | 2014-000995-24 | A double-blind, placebo-controlled two-part study to investigate the dose-ranging safety and pharmacokinetics, followed by the efficacy and safety of cannabidiol (GWP42003-P) in children and young adu... | 2015-11-26 | due-trials |
| Reported results | 2014-001834-27 | An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes | 2020-09-24 | due-trials |
| Reported results | 2014-002594-11 | A double blind, randomized, placebo-controlled, two-part study to investigate the pharmacokinetics, followed by efficacy and safety of GWP42006 as add-on therapy in patients with inadequately controll... | 2017-09-01 | due-trials |
| Reported results | 2014-002939-34 | A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome. | 2018-04-09 | due-trials |
| Reported results | 2014-002940-42 | A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox-Gastaut syndrom... | 2016-05-02 | due-trials |
| Reported results | 2014-002941-23 | A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox- Gastaut syndro... | 2016-02-26 | due-trials |
| Reported results | 2014-002942-33 | A phase 2, double-blind, randomized, placebo-controlled study to investigate possible drug-drug interactions between clobazam and cannabidiol (GWP42003-P) | 2017-06-07 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-002154-12 | A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experienc... | 2021-06-11 | bad-data |
| Reported results | 2015-002939-18 | A phase 2, double-blind, randomized, placebo-controlled pharmacokinetic trial in two parallel groups to investigate possible drug- drug interactions between stiripentol or valproate and GWP42003-P in ... | 2019-05-27 | due-trials |
| Reported results | 2015-004904-50 | A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of Cannabidiol (GWP42003-P) in infants with Infantile Spasms following an initial open label pilot study. | 2019-06-13 | due-trials |
| Exempt, with results | 2016-000936-17 | A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of GWP42003-P in Conjunction with Hypothermia in Neonates with Mod... | 2022-06-22 | not-yet-due |
| Ongoing, reported early | 2018-003370-27 | A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-P; CBD-OS) in patients with Rett syndrome. | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-001605-24 | An open-label extension trial to investigate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in patients with Rett Syndrome | 2021-03-24 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-002623-14 | A Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray as Add-on Therapy in Patients with Spasticity Due to Multiple Sclerosis | 2023-02-27 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-002625-29 | A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis | 2022-05-10 | bad-data |
| Reported results Terminated | 2019-003369-16 | A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants with Schizophrenia Experiencing Inadequate Re... | 2022-03-02 | due-trials |
| Trial is outside EEC | 2020-002132-67 | An Open-Label, Randomized Trial to Assess the Safety, Pharmacokinetics, and Exploratory Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) Compared with Standard of Care Antiseizure Medicat... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2020-002819-21 | An exploratory, Phase 2, randomized, double-blind, placebo-controlled trial to investigate the safety and efficacy of cannabidiol oral solution (GWP42003-P; CBD-OS) in children and adolescents with Au... | 2023-12-20 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2020-003271-18 | A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis Dv... | 2022-11-11 | bad-data |
| Ongoing | 2020-004306-58 | A randomized double-blind placebo-controlled study of nabiximols in patients with spasticity in multiple sclerosis | not-yet-due | |
| Completed, but no date, and reported results Terminated | 2021-003094-61 | A randomized, double-blind, placebo-controlled, multisite, Phase 3 study to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-P) in children and adolescents with epilepsy with... | bad-data |